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frequency of VH genes derived from the HIV Env-reactive blood
and colostrum B cells. However, VH gene subfamily 1*69 usage
wasmore frequent among colostrum-derived (51.4%) than blood-
derived (20.4%) HIV Env-reactive antibodies (p = 0.005, Fisher’s
exact test). In addition, colostrum contained a higher percentage
of gp120-directed antibodies and a lower percentage of gp41-
directed antibodies than blood (65.7 and 14.3% gp120-speciﬁc,
and 34.3 and 77.6% gp41-speciﬁc, respectively; p< 0.0001, Fisher’s
exact test). One cross-compartment HIV Env-speciﬁc clonal B cell
lineage was identiﬁed.
Conclusion: The IgG1 isotype predominance, more restricted VH
gene usage, and higher percentage of gp120-speciﬁcity of HIV
Env-speciﬁc antibodies isolated from colostrum B cells compared
to peripheral B cells of HIV-1-infected women suggest selective
homing of restricted populations of IgG-secreting memory B cells
to the lactating mammary gland. Thus, effective maternal vacci-
nation to eliminate postnatal virus transmission may require
speciﬁc targeting of this distinct population of mucosal B cells.
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Background: Due to the high level of structural variability of
HIV-1 Env, elicitation of neutralizing antibody (NAb) responses
to conserved neutralizing determinants, such as the CD4 binding
site (CD4bs), is a major focus of HIV-1 vaccine development.
Accordingly, a detailed understanding of how trimeric Env im-
munogens activate the naı¨ve primate B cell repertoire and how
Env-elicited antibody responses evolve during the course of the
immunization schedule may indicate how to direct the response
toward desired neutralizing targets.
Methods: Recently, we established methodology to characterize
NAb responses elicited by soluble Env immunogens in rhesus
macaques by antigen/epitope-speciﬁc single B cell sorting, RT-
PCR to recover immunoglobulin G (IgG) heavy/light chain
genes, in vitro expression of IgG, and epitope ﬁne-mapping to the
conserved CD4bs. Here, we extend the use of thismethodology to
conduct a comprehensive analysis of the evolving vaccine-elicited
CD4bs-speciﬁc B cell response at the clonal level.
Results: We interrogated the Ab repertoires from two rhesus
macaques following a total of ﬁve inoculations with trimeric Env.
We observed similar VH gene usage in the CD4bs- and Env-
speciﬁc memory B cell repertoires while the level of somatic
hypermutation was higher following the 5th immunization
compared to following the 2nd immunization in both compart-
ments. Interestingly, the heavy chain CDR3 regions from the
CD4bs-speciﬁc B cells were on average longer than those from the
total Env-speciﬁc cells and the CD4bs-speciﬁc B cell subset has
higher level of clonality than that of the Env-speciﬁc subset.
However, only a small portion of the CD4bs-speciﬁc Ig repertoire
following the 2nd immunization is maintained following the 5th
immunization, which suggests that clonality is only partially
maintained and the repertoire is dynamically recruiting new B
cells to generate diversity.
Conclusion: These data provide an improved understanding of
the evolving B cell response following Env immunization.
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Background: Advances in single cell antibody cloning methods
have led to the identiﬁcation of a variety of broadly neutralizing
anti-HIV-1 antibodies. Initial characterization of these anti-
bodies often involves measurement of their neutralization ac-
tivity against a panel of viruses, but such experiments do
not generally lead to conclusive identiﬁcation of an antibody’s
epitope.
Methods: We developed a computational tool, Antibody Data-
base, to help identify critical residues on Env whose natural
variation affects antibody activity. Our simplifying assumption
was that for a given antibody, a signiﬁcant portion of the dis-
persion of neutralization activity across a panel of HIV-1 strains is
due to the amino acid identity or glycosylation state at a small
number of speciﬁc sites, each acting independently. A model of
an antibody’s neutralization IC50 was developed in which each
site contributes a term to the logarithm of the modeled IC50. The
analysis program attempts to determine the set of rules that
minimizes the sum of the residuals between observed and mod-
eled IC50s.
Results: As a test case, we analyzed antibody 8ANC195, an anti-
gp120 antibody of unknown speciﬁcity. The model for this anti-
body indicated that glycosylation sites at Env positions 234 and
276 were critical for neutralization. We evaluated this prediction
by measuring neutralization potencies of 8ANC195 against
HIV-1 in vitro and in an antibody therapy experiment in hu-
manized mice.
Conclusion: These experiments conﬁrmed that 8ANC195 repre-
sents a distinct class of glycan-dependent anti-HIV-1 antibody
and validated the utility of computational analysis of neutrali-
zation panel data. The Antibody Database program imple-
ments this analysis as well as providing an environment where
sequence, neutralization, and structural data can be examined
together.
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Background: Previous studies suggested that poxvirus-based
vaccine regimens may be instrumental in the therapeutic HIV
ﬁeld. Here, we have characterized the T cell mediated immunity
elicited in 22 chronic HIV-1-infected patients undergoing highly
active antiretroviral therapy (HAART) pre- and post-vaccination
with a clade B-based HIV-1 vaccine candidate expressing Env,
Gag, Pol and Nef antigens (MVA-B).
Methods: A total of 30 chronic HIV-1-infected patients on
HAART with CD4 cell counts above 450 cells/mm3 and unde-
tectable viremiawere enrolled in a phase I, double-blind, placebo-
controlled trial. The volunteers were randomly allocated to
receive three injections of MVA-B (108 PFU/ dose) (n= 20) or
placebo (n = 10) by intramuscular route at weeks 0, 4 and 16
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